Shareholder Vote

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C.  20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): April 28, 2022 PFIZER INC . (Exact name of registrant as specified in its charter) Delaware 1-3619 13-5315170 (State or other (Commission File (I.R.S. Employer jurisdiction of Number) Identification No.) incorporation)     235 East 42nd Street 10017 New York, New York (Zip Code) (Address of principal executive offices) Registrant’s telephone number, including area code: ( 212 ) 733-2323 Not Applicable (Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the obligation of the registrant under any of the following provisions (see General Instruction A.2. below): ☐ Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2 (b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $.05 par value PFE New York Stock Exchange 1.000% Notes due 2027 PFE27 New York Stock Exchange Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company     ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.      ☐ Item 5.07   Submission of Matters to a Vote of Security Holders (a) The Pfizer Inc. (the "Company") Annual Meeting of Shareholders was held on April 28, 2022. (b) Shareholders voted on the matters set forth below. 1. The nominees for election to the Company’s Board of Directors set forth in Item 1 to the Company’s Proxy Statement filed with the U.S. Securities and Exchange Commission on March 17, 2022 were elected to hold office until the Company’s next Annual Meeting of Shareholders, based upon the following votes: Nominee Votes For  Votes Against Abstentions Broker non-vote Ronald E. Blaylock 3,701,357,646 97,026,302 10,925,480 849,628,501 Albert Bourla 3,577,655,169 204,869,446 26,783,357 849,628,501 Susan Desmond-Hellmann 3,744,546,772 54,872,805 9,887,325 849,628,501 Joseph J. Echevarria 3,315,350,611 483,108,900 10,848,394 849,628,501 Scott Gottlieb 3,775,202,986 23,651,661 10,414,283 849,628,501 Helen H. Hobbs 3,704,020,993 95,742,430 9,505,507 849,628,501 Susan Hockfield 3,773,537,829 25,701,939 10,029,162 849,628,501 Dan R. Littman 3,741,506,546 57,146,873 10,615,511 849,628,501 Shantanu Narayen 3,766,994,058 31,021,763 11,292,326 849,628,501 Suzanne Nora Johnson 3,605,854,757 193,599,113 9,854,277 849,628,501 James Quincey 3,729,849,039 68,041,486 11,406,359 849,628,501 James C. Smith 3,694,497,573 103,133,820 11,676,754 849,628,501 2. The proposal to ratify the selection of KPMG LLP as the Company’s independent registered public accounting firm for the 2022 fiscal year was approved based upon the following votes: Votes for approval 4,440,636,499 Votes against 204,291,133 Abstentions 14,009,991 Broker non-votes n/a 3. The proposal to approve, on an advisory basis, the compensation of the Company's Named Executive Officers was approved based upon the following votes : Votes for approval 3,509,011,827 Votes against 275,230,428 Abstentions 25,057,788 Broker non-votes 849,628,501 4. The shareholder proposal regarding amending proxy access was not approved based upon the following votes: Votes for approval 1,096,172,490 Votes against 2,686,465,588 Abstentions 26,655,147 Broker non-votes 849,628,501 5. The shareholder proposal regarding report on political expenditures congruency was not approved based upon the following votes: Votes for approval 393,729,907 Votes against 3,387,577,521 Abstentions 27,996,591 Broker non-votes 849,628,501 6. The shareholder proposal regarding report on transfer of intellectual property to potential COVID-19 manufacturers was not approved based upon the following votes: Votes for approval 1,023,141,083 Votes against 2,714,524,824 Abstentions 71,640,637 Broker non-votes 849,628,501 7. The shareholder proposal regarding report on board oversight of risks related to anticompetitive practices was not approved based upon the following votes: Votes for approval 1,138,551,810 Votes against 2,600,688,619 Abstentions 70,069,294 Broker non-votes 849,628,501 8. The shareholder proposal regarding report on public health costs of protecting vaccine technology was not approved based upon the following votes: Votes for approval 325,762,383 Votes against 3,415,442,745 Abstentions 68,096,240 Broker non-votes 849,628,501 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.   PFIZER INC.               By: /s/ Margaret M. Madden     Margaret M. Madden     Senior Vice President and Corporate Secretary     Chief Governance Counsel       Dated: May 2, 2022